CN Stock MarketDetailed Quotes

300122 Chongqing Zhifei Biological Products

Watchlist

27.93
-0.06-0.21%

Market Closed Dec 27 15:00 CST

66.86BMarket Cap18.11P/E (TTM)

Chongqing Zhifei Biological Products Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q9)Sep 30, 2024

(Q6)Jun 30, 2024

(Q3)Mar 31, 2024

(FY)Dec 31, 2023

(Q9)Sep 30, 2023

(Q6)Jun 30, 2023

(Q3)Mar 31, 2023

(FY)Dec 31, 2022

(Q9)Sep 30, 2022

(Q6)Jun 30, 2022

Total operating revenue

-41.98%22.79B

-25.31%18.26B

2.00%11.4B

38.30%52.92B

41.15%39.27B

33.19%24.45B

26.37%11.17B

24.83%38.26B

27.46%27.82B

39.34%18.35B

Operating revenue

-41.98%22.79B

-25.31%18.26B

2.00%11.4B

38.30%52.92B

41.15%39.27B

33.19%24.45B

26.37%11.17B

24.83%38.26B

27.46%27.82B

39.34%18.35B

Other operating revenue

----

4,427.67%115.66M

----

5.86%4.08M

----

18.55%2.55M

----

-83.58%3.85M

----

-84.84%2.15M

Total operating cost

-36.80%19.69B

-20.24%15.28B

8.45%9.32B

48.35%43.09B

47.80%31.15B

38.69%19.16B

32.19%8.6B

57.31%29.05B

78.26%21.07B

107.35%13.82B

Operating cost

-41.14%16.58B

-22.23%13.39B

8.22%8.43B

52.29%38.67B

51.56%28.17B

41.00%17.22B

32.79%7.79B

62.56%25.4B

85.16%18.59B

122.40%12.21B

Operating tax surcharges

-36.33%111.44M

-20.56%88.92M

0.96%50.14M

34.87%238.75M

37.39%175.03M

31.81%111.93M

35.60%49.66M

30.90%177.02M

30.75%127.39M

36.93%84.92M

Operating expense

4.95%1.94B

-5.90%1.12B

10.83%495.13M

24.04%2.77B

25.56%1.84B

24.71%1.19B

23.18%446.75M

21.82%2.24B

19.91%1.47B

22.18%950.67M

Administration expense

12.23%306.96M

10.60%202.93M

38.95%110.95M

5.05%393.03M

-0.85%273.5M

6.87%183.49M

10.80%79.85M

24.63%374.13M

37.30%275.84M

33.03%171.7M

Financial expense

54.26%54.31M

-6.35%20.59M

-69.57%5.96M

242.20%47.22M

379.40%35.21M

217.72%21.99M

178.72%19.6M

-36.77%13.8M

-62.63%7.34M

-82.34%6.92M

-Interest expense (Financial expense)

45.30%83.71M

24.11%49.23M

15.25%24.48M

51.98%81M

37.45%57.61M

41.25%39.66M

138.10%21.24M

-5.07%53.3M

-22.39%41.91M

-43.40%28.08M

-Interest Income (Financial expense)

-22.63%-57.76M

-52.04%-47.18M

-125.95%-29.66M

-47.40%-67.94M

-36.55%-47.1M

-44.64%-31.03M

-7.40%-13.13M

25.01%-46.09M

20.18%-34.49M

-33.32%-21.45M

Research and development

7.25%695.55M

5.60%461.35M

9.41%234.08M

13.38%968.47M

6.76%648.54M

12.68%436.88M

32.98%213.96M

54.56%854.16M

152.77%607.5M

138.26%387.72M

Credit Impairment Loss

-6.56%-605.07M

-25.14%-396.67M

-126.58%-340.79M

16.32%-352.71M

-122.44%-567.84M

-58.63%-316.98M

-11.84%-150.41M

-120.78%-421.51M

-59.90%-255.28M

-78.87%-199.83M

Asset Impairment Loss

77.07%-26.4M

80.88%-12.01M

97.03%-1.03M

-186.58%-311.99M

-264.91%-115.14M

-620.30%-62.79M

-223.84%-34.59M

-17.67%-108.87M

-567.91%-31.55M

-114.80%-8.72M

Other net revenue

-25.73%-615.71M

-25.38%-397.6M

-87.50%-335.67M

1.28%-449.97M

-109.96%-489.7M

-93.03%-317.11M

-161.21%-179.02M

-145.10%-455.79M

-75.71%-233.24M

-56.25%-164.28M

Asset deal income

-99.87%54.24K

-99.78%95.41K

----

618,276.31%41.37M

280,967.56%43.05M

281,852.30%43.19M

--41.78K

-82.90%6.69K

-14.47%15.32K

Other revenue

-89.54%15.71M

-43.60%10.99M

3.78%6.16M

132.43%173.36M

180.39%150.23M

-55.98%19.48M

-84.40%5.93M

-27.63%74.59M

38.41%53.58M

166.73%44.25M

Operating profit

-67.46%2.48B

-48.08%2.58B

-27.54%1.74B

7.02%9.37B

17.18%7.64B

13.57%4.97B

5.62%2.4B

-27.01%8.76B

-34.01%6.52B

-31.69%4.37B

Add:Non operating Income

138.62%38.09K

218.68%38.09K

83.63%18.52K

-44.80%337.69K

-89.19%15.96K

-91.29%11.95K

681.73%10.09K

230.76%611.76K

73.93%147.64K

191.58%137.18K

Less:Non operating expense

-59.53%6.79M

26.00%6.46M

-36.55%2.92M

-23.18%31.48M

-50.39%16.79M

-75.46%5.12M

-27.15%4.6M

-40.69%40.98M

-30.89%33.84M

-16.76%20.88M

Total profit

-67.48%2.48B

-48.16%2.57B

-27.53%1.73B

7.16%9.34B

17.53%7.62B

13.99%4.96B

5.71%2.39B

-26.93%8.72B

-34.02%6.48B

-31.75%4.35B

Less:Income tax cost

-69.94%327.33M

-51.83%338.38M

-23.38%276.02M

7.92%1.27B

24.37%1.09B

12.55%702.41M

5.89%360.26M

-31.55%1.18B

-38.42%875.41M

-29.69%624.11M

Net profit

-67.07%2.15B

-47.55%2.23B

-28.26%1.46B

7.04%8.07B

16.46%6.53B

14.24%4.26B

5.68%2.03B

-26.15%7.54B

-33.28%5.61B

-32.08%3.73B

Net profit from continuing operation

-67.07%2.15B

-47.55%2.23B

-28.26%1.46B

7.04%8.07B

16.46%6.53B

14.24%4.26B

5.68%2.03B

-26.15%7.54B

-33.28%5.61B

-32.08%3.73B

Net profit of parent company owners

-67.07%2.15B

-47.55%2.23B

-28.26%1.46B

7.04%8.07B

16.46%6.53B

14.24%4.26B

5.68%2.03B

-26.15%7.54B

-33.28%5.61B

-32.08%3.73B

Earning per share

Basic earning per share

-67.01%0.8976

-47.48%0.9322

-28.07%0.609

7.04%3.3624

16.47%2.721

14.24%1.775

-29.54%0.8467

-50.77%3.1412

-55.52%2.3363

-54.72%1.5538

Diluted earning per share

-67.01%0.8976

-47.48%0.9322

-28.07%0.609

7.04%3.3624

16.47%2.721

14.24%1.775

-29.54%0.8467

-50.77%3.1412

-55.52%2.3363

-54.72%1.5538

Other composite income

Total composite income

-67.07%2.15B

-47.55%2.23B

-28.26%1.46B

7.04%8.07B

16.46%6.53B

14.24%4.26B

5.68%2.03B

-26.15%7.54B

-33.28%5.61B

-32.08%3.73B

Total composite income of parent company owners

-67.07%2.15B

-47.55%2.23B

-28.26%1.46B

7.04%8.07B

16.46%6.53B

14.24%4.26B

5.68%2.03B

-26.15%7.54B

-33.28%5.61B

-32.08%3.73B

Currency Unit

CNY

Accounting Standards

CAS (2007)

Audit Opinions

Unqualified opinion

Auditor

Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership)

	(Q9)Sep 30, 2024	(Q6)Jun 30, 2024	(Q3)Mar 31, 2024	(FY)Dec 31, 2023	(Q9)Sep 30, 2023	(Q6)Jun 30, 2023	(Q3)Mar 31, 2023	(FY)Dec 31, 2022	(Q9)Sep 30, 2022	(Q6)Jun 30, 2022
Total operating revenue	-41.98%22.79B	-25.31%18.26B	2.00%11.4B	38.30%52.92B	41.15%39.27B	33.19%24.45B	26.37%11.17B	24.83%38.26B	27.46%27.82B	39.34%18.35B
Operating revenue	-41.98%22.79B	-25.31%18.26B	2.00%11.4B	38.30%52.92B	41.15%39.27B	33.19%24.45B	26.37%11.17B	24.83%38.26B	27.46%27.82B	39.34%18.35B
Other operating revenue	----	4,427.67%115.66M	----	5.86%4.08M	----	18.55%2.55M	----	-83.58%3.85M	----	-84.84%2.15M
Total operating cost	-36.80%19.69B	-20.24%15.28B	8.45%9.32B	48.35%43.09B	47.80%31.15B	38.69%19.16B	32.19%8.6B	57.31%29.05B	78.26%21.07B	107.35%13.82B
Operating cost	-41.14%16.58B	-22.23%13.39B	8.22%8.43B	52.29%38.67B	51.56%28.17B	41.00%17.22B	32.79%7.79B	62.56%25.4B	85.16%18.59B	122.40%12.21B
Operating tax surcharges	-36.33%111.44M	-20.56%88.92M	0.96%50.14M	34.87%238.75M	37.39%175.03M	31.81%111.93M	35.60%49.66M	30.90%177.02M	30.75%127.39M	36.93%84.92M
Operating expense	4.95%1.94B	-5.90%1.12B	10.83%495.13M	24.04%2.77B	25.56%1.84B	24.71%1.19B	23.18%446.75M	21.82%2.24B	19.91%1.47B	22.18%950.67M
Administration expense	12.23%306.96M	10.60%202.93M	38.95%110.95M	5.05%393.03M	-0.85%273.5M	6.87%183.49M	10.80%79.85M	24.63%374.13M	37.30%275.84M	33.03%171.7M
Financial expense	54.26%54.31M	-6.35%20.59M	-69.57%5.96M	242.20%47.22M	379.40%35.21M	217.72%21.99M	178.72%19.6M	-36.77%13.8M	-62.63%7.34M	-82.34%6.92M
-Interest expense (Financial expense)	45.30%83.71M	24.11%49.23M	15.25%24.48M	51.98%81M	37.45%57.61M	41.25%39.66M	138.10%21.24M	-5.07%53.3M	-22.39%41.91M	-43.40%28.08M
-Interest Income (Financial expense)	-22.63%-57.76M	-52.04%-47.18M	-125.95%-29.66M	-47.40%-67.94M	-36.55%-47.1M	-44.64%-31.03M	-7.40%-13.13M	25.01%-46.09M	20.18%-34.49M	-33.32%-21.45M
Research and development	7.25%695.55M	5.60%461.35M	9.41%234.08M	13.38%968.47M	6.76%648.54M	12.68%436.88M	32.98%213.96M	54.56%854.16M	152.77%607.5M	138.26%387.72M
Credit Impairment Loss	-6.56%-605.07M	-25.14%-396.67M	-126.58%-340.79M	16.32%-352.71M	-122.44%-567.84M	-58.63%-316.98M	-11.84%-150.41M	-120.78%-421.51M	-59.90%-255.28M	-78.87%-199.83M
Asset Impairment Loss	77.07%-26.4M	80.88%-12.01M	97.03%-1.03M	-186.58%-311.99M	-264.91%-115.14M	-620.30%-62.79M	-223.84%-34.59M	-17.67%-108.87M	-567.91%-31.55M	-114.80%-8.72M
Other net revenue	-25.73%-615.71M	-25.38%-397.6M	-87.50%-335.67M	1.28%-449.97M	-109.96%-489.7M	-93.03%-317.11M	-161.21%-179.02M	-145.10%-455.79M	-75.71%-233.24M	-56.25%-164.28M
Asset deal income	-99.87%54.24K	-99.78%95.41K	----	618,276.31%41.37M	280,967.56%43.05M	281,852.30%43.19M	--41.78K	-82.90%6.69K	-14.47%15.32K	-14.47%15.32K
Other revenue	-89.54%15.71M	-43.60%10.99M	3.78%6.16M	132.43%173.36M	180.39%150.23M	-55.98%19.48M	-84.40%5.93M	-27.63%74.59M	38.41%53.58M	166.73%44.25M
Operating profit	-67.46%2.48B	-48.08%2.58B	-27.54%1.74B	7.02%9.37B	17.18%7.64B	13.57%4.97B	5.62%2.4B	-27.01%8.76B	-34.01%6.52B	-31.69%4.37B
Add:Non operating Income	138.62%38.09K	218.68%38.09K	83.63%18.52K	-44.80%337.69K	-89.19%15.96K	-91.29%11.95K	681.73%10.09K	230.76%611.76K	73.93%147.64K	191.58%137.18K
Less:Non operating expense	-59.53%6.79M	26.00%6.46M	-36.55%2.92M	-23.18%31.48M	-50.39%16.79M	-75.46%5.12M	-27.15%4.6M	-40.69%40.98M	-30.89%33.84M	-16.76%20.88M
Total profit	-67.48%2.48B	-48.16%2.57B	-27.53%1.73B	7.16%9.34B	17.53%7.62B	13.99%4.96B	5.71%2.39B	-26.93%8.72B	-34.02%6.48B	-31.75%4.35B
Less:Income tax cost	-69.94%327.33M	-51.83%338.38M	-23.38%276.02M	7.92%1.27B	24.37%1.09B	12.55%702.41M	5.89%360.26M	-31.55%1.18B	-38.42%875.41M	-29.69%624.11M
Net profit	-67.07%2.15B	-47.55%2.23B	-28.26%1.46B	7.04%8.07B	16.46%6.53B	14.24%4.26B	5.68%2.03B	-26.15%7.54B	-33.28%5.61B	-32.08%3.73B
Net profit from continuing operation	-67.07%2.15B	-47.55%2.23B	-28.26%1.46B	7.04%8.07B	16.46%6.53B	14.24%4.26B	5.68%2.03B	-26.15%7.54B	-33.28%5.61B	-32.08%3.73B
Net profit of parent company owners	-67.07%2.15B	-47.55%2.23B	-28.26%1.46B	7.04%8.07B	16.46%6.53B	14.24%4.26B	5.68%2.03B	-26.15%7.54B	-33.28%5.61B	-32.08%3.73B
Earning per share
Basic earning per share	-67.01%0.8976	-47.48%0.9322	-28.07%0.609	7.04%3.3624	16.47%2.721	14.24%1.775	-29.54%0.8467	-50.77%3.1412	-55.52%2.3363	-54.72%1.5538
Diluted earning per share	-67.01%0.8976	-47.48%0.9322	-28.07%0.609	7.04%3.3624	16.47%2.721	14.24%1.775	-29.54%0.8467	-50.77%3.1412	-55.52%2.3363	-54.72%1.5538
Other composite income
Total composite income	-67.07%2.15B	-47.55%2.23B	-28.26%1.46B	7.04%8.07B	16.46%6.53B	14.24%4.26B	5.68%2.03B	-26.15%7.54B	-33.28%5.61B	-32.08%3.73B
Total composite income of parent company owners	-67.07%2.15B	-47.55%2.23B	-28.26%1.46B	7.04%8.07B	16.46%6.53B	14.24%4.26B	5.68%2.03B	-26.15%7.54B	-33.28%5.61B	-32.08%3.73B
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)
Audit Opinions	--	--	--	Unqualified opinion	--	--	--	Unqualified opinion	--	--
Auditor	--	--	--	Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership)	--	--	--	Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership)	--	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List

Overall

No Data

300122 Chongqing Zhifei Biological Products

Chongqing Zhifei Biological Products Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow